Understanding rare neurodevelopmental disorders (NDD) has the potential drive major new therapies for the common NDD of schizophrenia and Autism Spectrum Disorder (ASD).
NDD affect 1 in 25 individuals in Europe and have high impact on healthcare systems, economic development and society. Our key challenge is to link new knowledge from psychiatric genomics to identify neurobiological mechanisms that lead to NDD.